Considering the synergistic effects of ERα signaling and HER2 overexpression on cell cycle checkpoints, as well as multiple feedback loops between these pathways, there is a strong signaling rationale to combine CDK4/6 inhibitors with HER2 inhibitors and antihormonal agents for treatment of HR+/HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.